A Phase II Study of Temozolomide in the Treatment of Recurrent Malignant Gliomas
- Determine the progression-free survival and response rate of patients with recurrent or
progressive malignant glioma treated with temozolomide.
- Determine whether certain categories of malignant gliomas, such as oligodendroglioma,
are more sensitive to temozolomide.
- Determine the toxicity of this regimen in these patients.
OUTLINE: Patients are stratified according to histologic categories (recurrent glioblastoma
multiforme [closed to accrual 11/30/01] vs recurrent anaplastic astrocytoma vs recurrent
Patients receive oral temozolomide twice daily for 5 consecutive days. Courses repeat every
28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 3 years.
Primary Purpose: Treatment
Casilda Balmaceda, MD
Herbert Irving Comprehensive Cancer Center
United States: Federal Government
|Stanford University Medical Center||Stanford, California 94305-5408|
|Cancer Center of Albany Medical Center||Albany, New York 12208|
|University of Pennsylvania Cancer Center||Philadelphia, Pennsylvania 19104|
|Robert H. Lurie Comprehensive Cancer Center, Northwestern University||Chicago, Illinois 60611|
|Cleveland Clinic Taussig Cancer Center||Cleveland, Ohio 44195|
|Herbert Irving Comprehensive Cancer Center||New York, New York 10032|
|Mount Sinai Comprehensive Cancer Center||Miami Beach, Florida 33140|
|Froedtert Memorial Lutheran Hospital||Milwaukee, Wisconsin 53226|
|Nalitt Institute for Cancer And Blood Related Diseases||Staten Island, New York 10305|
|Neurological Clinic||Portland, Oregon 97210|